U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07848191) titled 'Rezdiffra(R) With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis' on Aug. 25.
Brief Summary: To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin & Actos/pioglitazone)
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Intervention:
DRUG: Rezdiffra
All study medications will be administered according to their labels:
* REZDIFFRA- Label weight-based dosing:
* =100 kg: 100 mg orally once daily
DRUG: Resmetirom
R...